Quantcast

Pulmonary Langerhans Cell Histiocytosis and Other Pulmonary Histiocytic Diseases: A Review

July 16, 2008

By Allen, Timothy Craig

* Context.-Pulmonary Langerhans cell histiocytosis is the most common and best known pulmonary histocytic lesion; however, the realm of pulmonary histiocytic lesions also includes an assortment of uncommon diseases that may exhibit pulmonary involvement. Objective.-To review pulmonary Langerhans cell histiocytosis and other pulmonary histiocytoses to better ensure correct diagnosis and optimal assessment of prognosis and treatment.

Data Sources.-Literature review and primary material from the author’s institution.

Conclusions.-This review discusses the most common pulmonary histocytosis, pulmonary Langerhans cell histiocytosis, and also reviews the uncommon pulmonary histiocytic lesions, which are distinct from pulmonary Langerhans cell histiocytosis.

(Arch Pathol Lab Med. 2008;132:1171-1181)

Pulmonary Langerhans cell histiocytosis (PLCH) is the most common and best known pulmonary histocytic lesion; however, the realm of pulmonary histiocytic lesions also includes an assortment of uncommon diseases that may exhibit pulmonary involvement. This review discusses the most common pulmonary histocytosis, PLCH, and also reviews the uncommon pulmonary histiocytic lesions that are distinct from PLCH.

The pulmonary histiocytoses are diseases characterized by the accumulation of histiocytes within the airspaces or parenchyma of the lung. This diverse group of disorders includes dendritic cell disorders, macrophage diseases, and storage diseases. The Histocyte Society classifies histiocytic diseases as dendritic cell-related disorders such as Langerhans cell histiocytosis, xanthogranulomatous disorders such as Erdheim-Chester disease, macrophage-related disorders such as Rosai-Dorfman disease, and malignant disorders such as dendritic cell-related histiocytic sarcoma.1,2 Langerhans cell histiocytosis is a term for a variety of diseases characterized by the proliferation and infiltration of Langerhans cells into various organs.3-8 Several terms have been used in the past to denote multisystem lesions predominantly arising in children, including Letterer-Siwe disease, Hand-Schu ller-Christian syndrome, histiocytosis X, and Hashimoto Pritzker syndrome.8 Multisystem Langerhans cell histiocytosis may exhibit lung involvement. Eosinophilic granuloma and histiocytosis X are terms that have frequently been used in the past to designate localized pulmonary lesions.8 The characteristic feature of all lesions designated Langerhans cell histiocytosis, from any site, is the infiltration Langerhans cells-CD1a-positive histiocytes of dendritic lineage derived from CD34-positive bone marrow stem cells. Langerhans cells play a role in the induction of primary antigen-specific immune reactions, play a key role in immunity, and are found in many tissues. These pulmonary dendritic cells are leukocytes that have been found to play a key role in immune response in the lung.9 Pulmonary Langerhans cell histiocytosis, in contrast to the systemic Langerhans cell histiocytoses typically found in childhood that are clonal neoplastic diseases, consists of nonneoplastic collections of reactive Langerhans cells.6,10-13

Pulmonary Langerhans cell histiocytosis is an interstitial lung disease occurring predominantly in adult cigarette smokers.14-16 Smokers have been shown to have an increased total number of T lymphocytes and a decreased helper-induced-suppressor-cytotoxic T lymphocyte (T4/T8) ratio compared with nonsmokers, potentially reducing helper-inducer lymphocytes that facilitate B-lymphocyte proliferation.17 Alveolar macrophages in smokers may be activated by materials in tobacco smoke causing them to release chemotactic factors with a resultant increase in peripheral blood monocytes within the lung.18,19 Pulmonary neuroendocrine cell stimulation by cigarette smoke may cause neuroendocrine cell hyperplasia in some smokers, with resultant increased recruitment of monocyte differentiation into Langerhans cells and associated fibroblast stimulation by bombesin-like peptides.20 Macrophage colony- stimulating factor and platelet-derived growth factor may also play a role in initiating and maintaining PLCH pathology.21 Langerhans cells in PLCH are phenotypically similar to mature lymphostimulatory dendritic cells within lymphoid organs, and the pathogenesis of PLCH may be related to an abnormal immune response by these Langerhans cells.22

Clinically, PLCH is uncommon, comprising approximately 5% of all interstitial lung disease cases, generally occurring in middle-aged men and women.23,24 Presenting symptoms are variable and include dyspnea, nonproductive cough, malaise, fever, weight loss, and night sweats. Patients may present with hemoptysis. Patients may be asymptomatic and be identified radiographically. Pneumothorax, sometimes recurrent, occurs in one fourth of patients during their disease course. Physical examination may also show variable features, including pulmonary rhonchi, rales, and wheezes, as well as decreased breath sounds. With increasing severity of disease, patients typically exhibit decreased diffusing capacity.25 Radiographically, most patients have x-ray abnormalities of varying degrees. Reticular changes, micronodules measuring 2 to 5 mm, and cysts measuring up to 1 cm have been commonly observed in PLCH patients.26 Pulmonary Langerhans cell histiocytosis can rarely progress to end-stage lung change, with characteristic radiologic changes of honeycombing present.

Pulmonary Langerhans cell histiocytosis is typically diagnosed from open lung biopsy, and gross appearance varies according to disease progression.4 Wedge biopsies of early lesions show multiple well-demarcated grey-white to tan-white irregular, stellate nodules ranging from less than 1 cm to about 2 cm. With evolution of PLCH, lesions show increasing amounts of stellate fibrosis and cyst formation. 4 Pathologically, early PLCH lesions consist of discrete bronchiolocentric stellate nodules (Figures 1 and 2). Early lesions are more cellular and less fibrotic than more mature lesions and consist of a variable mix of Langerhans cells, lymphocytes, eosinophils, and plasma cells with a background of generally mild fibrosis (Figures 3 through 5). Fibrosis replaces the cellular nodules as disease progresses, and less cellular stellate nodules are formed (Figure 6). Few Langerhans cell histiocytes and variable numbers of eosinophils may be found in these more fibrotic nodules. Surrounding lung may contain smoker’s pigment-laden alveolar macrophages arranged in a desquamative interstitial pneumonia-like pattern4 (Figure 7). Surrounding lung may retract with resultant airspace enlargement (Figure 8). Coalescence of nodules and the formation of large cysts are later occurrences, with some cases progressing to end-stage lung changes with honeycombing (Figure 9). Pulmonary Langerhans cell histiocytosis patients frequently have changes of early to late stage disease, both of which may be identifiable in a wedge biopsy. Langerhans cells usually are immunopositive with CD1a, Langerin, E-cadherin, and S1004,27,28 (Figures 10 and 11). Birbeck granules, also termed Langerhans cell granules, pentalaminar rod-shaped cytoplasmic organelles with a racket- or rod-shaped appearance, are found ultrastructurally. 29

The primary therapy for PLCH is smoking cessation.4 Anecdotal reports have shown patient improvement from corticosteroid therapy, and patients with progressive disease have been treated with chemotherapy such as cyclophosphamide and methotrexate; however, no randomized study has been performed to assess the benefit of these therapies.4 Pulmonary Langerhans cell histiocytosis patients have variable prognoses. About one fourth of patients will regress spontaneously whether or not they stop smoking, about half of patients will stabilize but not regress spontaneously, and about one fourth of patients will exhibit progressive disease that may ultimately cause honeycombing. 14,30,31 Pleurodesis in PLCH patients presenting with spontaneous pneumothorax may be of benefit.32 The differential diagnosis of PLCH varies depending on whether early PLCH lesions or late lesions, or both, are present in the biopsy. Early, cellular PLCH nodules containing many eosinophils are suggestive of eosinophilic pneumonia; however, in contrast to PLCH, eosinophilic pneumonia generally is composed of collections of eosinophils and macrophages lying within alveolar spaces, as well as an interstitial infiltrate of variable degree made up of lymphocytes, macrophages, and eosinophils. Desquamative interstitial pneumonia should be considered in the differential diagnosis when the biopsy predominantly contains smoker’s pigment-laden macrophages lying within alveolar spaces. It is important to consider that respiratory bronchiolitis-associated interstitial lung disease/ desquamative interstitial pneumonia is another smokingrelated disease and may occasionally coexist with PLCH. In later stage PLCH, with its more fibrotic and scarred lesions, ultimately causing honeycombing, usual interstitial pneumonia becomes a differential diagnosis. Usual interstitial pneumonia is predominantly a subpleural disease usually involving the lower zones of the lungs. Pulmonary Erdheim-Chester disease is a differential diagnosis that is discussed later.33-35

ROSAI-DORFMAN DISEASE

Sinus histiocytosis with massive lymphadenopathy, also termed Rosai-Dorfman disease, is a rare nonmalignant proliferation of histiocytic/phagocytic cells of unknown etiology occurring within lymph node sinuses, lymphatics, and various extranodal sites.36-38 It typically occurs in children and young adults.36,38 No clinical response with antibacterial or antitubercular therapies have been documented, and viral infection and disordered immune regulation have been hypothesized as possible etiologies.36 An exuberant hematopoietic system response to an unknown immunologic trigger has been considered a possible cause.36 The association of Rosai- Dorfman disease with autoimmune lymphoproliferative syndrome, an inherited disorder of lymphocyte programmed cell death primarily occurring in early childhood, and the identification of mutations of the Fas gene in a small subset of Rosai-Dorfman disease patients suggests that Rosai-Dorf man disease may represent an acquired disorder of apoptotic signaling pathway regulation.36,39-42 Rosai- Dorfman disease most frequently presents as painless massive, often cervical, lymphadenopathy.36,43 Nodal disease is frequently self- limited.43 Extranodal involvement of various sites including bone, retro-orbital tissue, skin, lung, and kidneys occurs in approximately 20% to 40% of patients.38,44 Skin and soft tissue, nasal and paranasal sinuses, the eye and ocular adnexa, and bone are the most common extranodal sites of involvement.36 Pulmonary involvement is rare and occurs in approximately 2% to 3% of cases with extranodal disease.36,45,46 It usually presents as solitary or multiple mass lesions in the lung, bronchi, or trachea, typically with coexisting nodal and extranodal disease.45-49 The tracheobronchial tree is most commonly involved with pulmonary Rosai- Dorfman disease, presenting as large single or multiple airway masses; however, diffuse interstitial lung involvement may rarely occur, and primarily pleural disease has been reported.45 Radiographically, mediastinal fullness or nodal enlargement or hilar or perihilar masses may be present.46-49 Diffuse lung involvement may present radiographically as bilateral reticulonodular infiltrates.

Histologically, pulmonary Rosai-Dorfman disease exhibits an infiltrate of faintly staining histiocytes with oval nuclei that may contain mild atypia, one or more nucleoli, and abundant pale eosinophilic cytoplasm.36 The histiocytes lie in an inflammatory background of scattered plasma cells and lymphocytes. Lymphocytes within histiocyte cytoplasm, termed lymphophagocytosis or emperipolesis, is a distinctive feature of Rosai-Dorfman disease36,46 (Figures 12 and 13). Usually located within cytoplasmic vacuoles, these lymphocytes avoid degradation as they transit through the histiocyte.36 Surrounding lung parenchyma generally contains a mixture of inflammatory cells, fibrosis, foamy alveolar macrophages, and a proliferation of type II pneumocytes. Immunopositivity with S100 is the most useful immunomarker for Rosai- Dorfman disease.36 Histiocytes in Rosai-Dorfman disease also typically show immunopositivity with CD68, CD14, CD15, CD163, and alpha^sub 1^-antichymotrypsin and immunonegativity with CD1a and factor XIIIa.36,37

Most cases of Rosai-Dorfman disease limited to nodal disease exhibit spontaneous resolution.36 Pulmonary disease, renal disease, and hepatic disease with associated immunogenic dysfunction frequently show persistent lymphadenopathy or disease dissemination.36 Treatment for Rosai-Dorfman disease varies with disease severity. Uncomplicated cases may be observed; however, disease that is widely disseminated, which manifests organ compression, may require surgical debulking, radiation therapy, or both.36 Chemotherapy has not shown obvious benefit and is not a primary treatment.36 Prognosis varies, but for patients with pulmonary Rosai-Dorfman disease, prognosis is guarded.45 Patient mortality of 45% has been reported, with 33% of patients exhibiting persistent or progressive disease.45,46 The differential diagnosis of pulmonary involvement with Rosai-Dorfman disease includes PLCH, Erdheim-Chester disease, carcinoma, Hodgkin lymphoma, Gaucher disease, and mycobacterial and fungal infections, among others.6 The eosinophils often present in lesions of PLCH are not a usual feature of pulmonary Rosai-Dorfman disease.36 The characteristic bilateral and symmetric osteosclerosis of long bones present with Erdheim- Chester disease is helpful in differentiating it from Rosai-Dorfman disease, as is its lack of emperipolesis. Indeed, emperipolesis is rarely a feature seen outside of the setting of Rosai-Dorfman disease.36

ERDHEIM-CHESTER DISEASE

Erdheim-Chester disease, identified by William Chester in 1930, is a rare, systemic, nonfamilial non-Langerhans cell histiocytosis of unclear, but possibly clonal, etiology that occurs predominantly in middle-aged and older adults.33-35,50-53 Bone pain is the typical presenting complaint, and the disease is characterized clinically and radiographically by symmetric osteosclerosis that involves the metaphyses and diaphyses of long bones.33,35,52 Almost pathognomonic, symmetrical sclerotic or mixed sclerotic and lytic lesions involving the metaphyseal and diaphyseal regions of long bones can be seen on skeletal radiographs. 35 Approximately half of Erdheim-Chester disease patients exhibit extraskeletal disease, including lung, heart, skin, kidney, retroperitoneum, retro-orbital and periorbital tissues, breast, pituitary-hypothalamic axis, sinonasal mucosa, and skeletal muscle.35,53 Twenty percent to 35% of patients exhibit pulmonary involvement.33,35,50,54

Patients having lung involvement typically present with cough and progressive dyspnea, and decreased diffusing capacity is frequently a feature.35,52,55 A pleural effusion may be present.35,52 Chest x- ray often exhibits diffuse interstitial infiltrates with pleural and interlobular septal thickening and may show a relatively nonspecific pattern of interstitial opacities, generally in the upper lung zones.35 Pleural thickening may occur, occasionally being the prevalent radiographic change.33 Interlobular and visceral pleural thickening with patchy reticular and centrilobular opacities, areas of ground glass attenuation, and pleural effusion are frequent findings on chest computed tomography scan.33 Combined with the typical clinical and radiographic skeletal findings, the radiographic findings of smooth interlobular septal thickening and centrilobular nodular opacities, fissural thickening, and pleural effusions are highly suggestive of Erdheim-Chester disease. 56

Transbronchial biopsies of Erdheim-Chester disease are unhelpful in showing the distribution of this interstitial lung disease, but wedge biopsy specimens are able to exhibit diagnostic features.51 Histologically, lung involvement with Erdheim-Chester disease generally shows a histiocytic and lymphocytic infiltrate arranged in a lymphangitic pattern, as well as diffuse interstitial thickening and variable fibrosis, and the accumulation of foamy to clear histiocytes within alveolar spaces35 (Figures 14 and 15). Approximately two thirds of patients with lung involvement have a bronchovascular, subpleural, and/or interlobar septal distribution of the lymphangitic infiltrate.35 Pleural and subpleural fibrosis may be identified extending into underlying lung parenchyma along the interlobular septa.33-35 The histiocytes within the inflammatory infiltrate in Erdheim-Chester disease have abundant palestaining cytoplasm; however, they do not exhibit nuclear folding or eosinophilic cytoplasm that characterize the Langerhans histiocytes of PLCH33,35 (Figures 16 and 17). The histiocytes in Erdheim- Chester disease characteristically exhibit CD68 and factor XIIIa immunopositivity and CD1a immunonegativity33-35 (Figure 18). Immunostain with S100 is variably positive, possibly because of the presence of S100-positive reactive histiocytes within the fibrohistiocytic areas.35 Birbeck granules are not present ultrastructurally within Erdheim-Chester disease histiocytes, in contrast to PLCH Langerhans histiocytes.33,35

Treatments and therapeutic responses are infrequently discussed in case reports of pulmonary involvement with Erdheim-Chester disease51,57; however, reported therapies include steroids, interferon, cytotoxic chemotherapy, surgery, stem cell transplantation, and radiation.35,51 The rarity of cases has precluded therapeutic standardization.51 Poor or variable success has been shown, with the most successful anecdotal cases using a combination of a chemotherapeutic agent and prednisone.35,51 Patients’ courses have been variable, with some patients maintaining stable extraosseous disease over time and other patients exhibiting progressive disease leading to death because of extraosseous, often pulmonary or retroperitoneal, disease. Prognosis in these patients is generally dependent on the extent of extraosseous disease, and approximately 60% of patients die of disease within 3 years, mostly from pulmonary or retroperitoneal disease.33-35,57 One third of patients with lung involvement die of disease within 6 months.35

Differential diagnosis of Erdheim-Chester disease in the lung includes other interstitial lung diseases such as usual interstitial pneumonia and nonspecific interstitial pneumonia, other histiocytic lesions such as Rosai-Dorfman disease and PLCH, sarcoidosis, and storage diseases.35,54 Correct diagnosis typically requires correlation of the patient’s history, physical examination, and radiologic studies with histology and immunohistochemistry.35,57 The characteristic lymphangitic distribution of Erdheim-Chester disease, as well as CD1a immunonegativity and absence of Birbeck granules in histiocytes, are helpful in distinguishing it from PLCH, usual interstitial pneumonia, and other differential diagnoses.

GAUCHER DISEASE

Gaucher disease, the most prevalent lysosomal storage disorder, is an autosomal recessive lipid storage disease caused by glucocerebrosidase deficiency.58-63 The adult form of the disease, type I, typically involves bone, spleen, and liver, and pulmonary involvement is uncommon and generally exhibited only in association with disease in the more common organs.61,62,64-68 Type I disease is especially prevalent in the Ashkenazi Jew population and is much more common than type II and type III disease, differing from those types by sparing of the central nervous system. 61,62 Type II disease, also termed acute neuropathic type, is generally found in children by age 6 months, and type III disease is a juvenile form of disease also termed the subacute neuropathic form.62 A glucocerebroside gene mutation with resultant diminished enzymatic activity causes increased accumulation of glucocerebroside in lysosomes of phagocytic Gaucher cells.62,69 Hepatosplenomegaly, bone pain and pathologic fractures, anemia, and easy bruising are frequently identified symptoms. Patients with severe disease, especially in disease with neuropathic changes, are more likely to exhibit pulmonary disease.63 Histologically, lung involvement with Gaucher disease may be multifaceted.61-65 Gaucher cells may fill alveolar spaces, as well as septa, with resultant interstitial lung disease.62,63 Pulmonary hypertension may occur, with or without the involvement and subsequent occlusion of alveolar septal capillaries or other vessels with Gaucher cells.62,63 Gaucher cells exhibit a “wrinkled paper” appearance, highlighted with periodic acid-Schiff stain (Figure 19). In contrast to alveolar macrophages, Gaucher cells usually exhibit relatively light CD68 immunopositivity. Enzyme replacement therapy has been found to be safe and effective in reducing hepatosplenomegaly and improving hematologic parameters; however, pulmonary manifestations of Gaucher disease have not shown a similar response to such therapy.63,70 Bilateral lung transplant has been reported.62 Research positing that glucocerebrosidase secretion is related to its delivery to lysosomes by interaction with transmembrane protein LIMP-2 suggests the potential for improved future therapy for Gaucher disease patients.71

FABRY DISEASE

Fabry disease is an X-linked metabolic disease caused by alpha- galactosidase A deficiency, with resultant accumulation of glycosphingolipids, predominantly globotriaosylceramide, throughout the body, including the lungs.72-75 Patients with Fabry disease can exhibit a variety of pulmonary signs and symptoms including dyspnea, wheezing, pneumothorax, airway obstruction, and hemoptysis.75 Airway obstruction is more common in older patients, many of whom are smokers.75,76 Frameshift mutations as well as the missense mutation D24V are also associated with airway obstruction.76 Chest x-ray is frequently normal; however, airflow limitation may be demonstrated by pulmonary function studies.75 Chest computed tomography may show ground glass opacities, possibly representing alveolar filling by glycosphingolipid.75 Histologically, diagnostic laminated inclusions can be found in capillary endothelium; type II pneumocytes, ciliated bronchial mu cosal cells, and goblet cells are generally found in bronchial biopsy specimens, brushings, or lavage fluid.72,76-78 Diagnosis via sputum cytology has been reported.72 Enzyme replacement therapy using enzymatically active human alpha- galactosidase A became available in 2003 and has been shown to alleviate pulmonary dysfunction in some patients.73-75

NIEMANN-PICK DISEASE

Niemann-Pick disease is a term used to describe rare, inherited autosomal recessive disorders characterized by an absence or deficiency of the enzyme acid sphingomyelinase and resulting in increased sphingomyelin deposition within reticuloendothelial cells.79-82 Types A and B Niemann-Pick disease are lysosomal storage disorders showing symptoms caused by the accumulations of lipid laden macrophages, called Niemann-Pick cells, in a variety of organs, specifically spleen and liver.80 Type C disease is a complex lipid storage disorder caused by cholesterol trafficking defects because of mutations in the NPC1 and NPC2 genes.79,80 Type A disease usually causes death by about age 3 years; however, patients with type B disease show phenotypic variability and some residual enzyme activity, with patients frequently living into adulthood. 79-81 Lung involvement is relatively frequent in infantile forms of Niemann- Pick disease but is an uncommon finding in adult forms.

Lung disease may be present in patients with type A disease; however, the lungs are typically spared in patients with type C disease, especially in adults.79,80 Lung involvement in patients with type C Niemann-Pick disease has been reported.80-83 Lung involvement is a common finding in patients with type B disease.80 Adult patients with type B disease frequently exhibit hepatosplenomegaly, but lung involvement may be asymptomatic and detected only on chest x-ray.80 Mild, recurrent cough or dyspnea on exertion may be present.80 Chest x-ray and computed tomography scan often show nonspecific bilateral interstitial reticulonodular changes, sometimes with diffuse honeycombing in lung bases, establishing the presence of interstitial lung disease.79-81 Radiologic studies do not assist in determining the severity of disease or predicting clinical outcome.80

Grossly, the lung in Niemann-Pick disease is often heavy and pale.84 Histologically, the lungs frequently show endogenous lipid pneumonia consisting of alveolar filling by Niemann-Pick cells.79,85,86 Areas of interstitial foamy macrophages, variable interstitial fibrosis, and often foamy change within ciliated mucosal epithelium are found.79 Pleura and lymphatics may also be involved.85,86 Niemann-Pick histiocytes are generally enlarged with abundant finely vacuolated cytoplasm and eccentric nuclei87 (Figures 20 and 21). The cells are usually immunopositive with CD68.88 Strong blue staining of Niemann-Pick cells with May-Grunwald Giemsa stain, called “sea blue histiocytosis,” is a nonspecific feature.85,88 Concentric lamellar myelin-like lysosomal inclusions are an ultrastructural feature of the disease.86 Treatment by whole lung lavage has been described, and bone marrow transplantation has been attempted in some patients.79,89,90 Differential diagnosis includes other causes of endogenous lipid pneumonia, including peritumoral disease, and drug therapy, specifically amiodarone therapy with associated toxicity.79 Progression of lung disease is generally slow and unremitting, but cases of rapidly fatal lung disease have been reported.80,91,92

HERMANSKY-PUDLAK SYNDROME

Hermansky-Pudlak syndrome, also termed oculocutaneous albinism syndrome, is a rare heterogeneously inherited autosomal recessive disease characterized by the systemic accumulation of ceroid-filled histiocytes, considered to be a consequence of disturbed formation or trafficking of intracellular vesicles, specifically melanosomes, platelet dense granules, and lysosomes.93-95 Patients frequently have oculocutaneous albinism, with associated decreased visual acuity, congenital nystagmus, and iris transillumination; variable skin and hair hypopigmentation; and bruising.93-96 Patients may have prolonged bleeding time caused by platelet aggregation defects.93,96 Ceroid deposition involves many organs and causes increased morbidity in the lungs, often leading to death in patients’ fourth or fifth decades of life because of pulmonary fibrosis. 93 Pulmonary macrophages are abnormal, and type II pneumocytes are disrupted.93,97 The gene mutation causing Hermansky-Pudlak syndrome is one of the most prevalent single-gene disorders in northwest Puerto Rico.93 Clinical and radiologic features of interstitial lung disease may occur, usually causing disease by the patients’ fourth or fifth decade of life and death by the fifth decade.93 Approximately 50% of patient deaths are because of pulmonary fibrosis.93 The pathogenesis of pulmonary fibrosis is uncertain; however, intracellular disruption of type II pneumocytes by ceroid, causing a cascade of inflammation, cytokine reduction, and fibroblast proliferation, may ultimately cause the development of pulmonary fibrosis.93 A usual interstitial pneumonia-like pattern or a nonspecific interstitial pneumonia-like pattern of fibrosis is seen in the lung histologically. Ceroid-filled histiocytes are usually located within air spaces and interstitial septa (Figures 22 and 23). Prevention or minimization of bleeding is an important therapeutic goal, as is the prevention or minimization of lung fibrosis.93 Therapies such as corticosteroids, cyclophosphamide, cyclosporine, and azathioprine often cause deleterious side effects such as myelosuppression, oncogenesis, and lung toxicity, without inhibiting disease progression.93 Pirfenidone, with anti- inflammatory, antioxidant, and antifibrotic properties, has been investigated with a randomized placebo-controlled trial and has shown an approximately 8% slower decline in pulmonary function in patients compared with a control group.93,98 Bilateral lung transplantation has been reported, with the patient stable at 12 months posttransplant. 95

DIABETIC XANTHROGRANULOMA

Reinila,99 in a study of 339 autopsy lung samples, found perivascular collections of foamy histiocytes in 20 (5.9%) lung samples from diabetic patients versus 3 (1.9%) samples of control patients. The perivascular collections measured an average of 176 [mu]m, and periodic acid-Schiff and iron stains were negative.99 The author hypothesized that some dysfunction in lipid transport through the vessel wall might be causative.99

CHOLESTERYL ESTER STORAGE DISEASE

Cholesteryl ester storage disease is an autosomal recessive storage disease that typically results in chronic liver disease.100 It is caused by partial lysosomal acid lipase/cholesteryl ester hydrolase deficiency because of mutation of the gene encoding for lysosomal acid lipase, located on chromosome 10q23.2-q23.3.100 Wolman disease, in which there is complete enzyme deficiency, is typically fatal within the first 6 months of life.100 Most patients are carriers of exon 8 splice junction mutation, leading to an inframe deletion of exon 8 with the resultant protein having no residual lysosomal acid lipase activity.100-107 Disease usually begins in childhood or adolescence, and both males and females are equally affected.100 Survival to age 30 years is rare.100 Deposition of cholesteryl ester usually occurs within the spleen, liver, bone marrow, and intestine. 108 Lung involvement is rare.109 Intracytoplasmic accumulation of cholesterol esters within alveolar macrophages, fibroblasts, and interstitial cells occurs histologically, and pulmonary arteries may contain focal concentric intimal deposits of foam cells and extracellular lipid109,110 (Figure 24). References

1. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. Med Pediatr Oncol. 1997;29:157-166.

2. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:221-246.

3. Caminati A, Harari S. Smoking-related interstitial pneumonias and pulmonary Langerhans cell histiocytosis. Proc Am Thorac Soc. 2006;299-306.

4. Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. Eur Respir J. 2006; 27:1272-1285.

5. Vassallo R, Ryu JH, Colby TV, et al. Medical progress: pulmonary Langerhans’ cell histiocytosis. N Engl J Med. 2000;346:1969-1978.

6. Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans’ cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol. 2001;25:630-636.

7. Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med. 2002;346:484-490.

8. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults: report from the International Registry of the Histiocyte Society. Eur J Cancer. 2003;39:2341-2348.

9. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am J Respir Crit Care Med. 2005;172:530-531.

10. Dacic S, Trusky C, Bakker A, et al. Genotypic analysis of pulmonary Langerhans’ histiocytosis. Hum Pathol. 2003;34:1345-1349.

11. Willman CL, Busque L, Griffith BB, et al. Langerhans’ cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med. 1994;331:154-160.

12. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans’ cells in Langerhans’ cell histiocytosis. Lancet. 1994;343:767-768.

13. Willman CL. Detection of clonal histiocytes in Langerhans’ cell histiocytosis: biology and clinical significance. Br J Cancer Suppl. 1994;23:S29-S33.

14. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung: clinical aspects of primary pulmonary histiocytosis in the adult. Medicine (Baltimore). 1981;60:385-396.

15. Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans’ cell histiocytosis (histiocytosis X): a clinicopathologic study of 48 cases. Am J Surg Pathol. 1993;17:971-986.

16. Schonfeld N, Frank W, Wenig S, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration (Herrlisheim). 1993;60:38-44.

17. Miller LG, Goldstein G, Murphy M, Ginns LC. Reversible alterations in immunoregulatory T cells in smoking: analysis by monoclonal antibodies and flow cytometry. Chest. 1 1982;82:526-529.

18. Senior RM, Kuhn C III. The pathogenesis of emphysema. In: Fishman AP, ed. Pulmonary Diseases and Disorders. 2nd ed. New York, NY: McGraw-Hill; 1988:1209-1219.

19. Hoogsteden HC, van Hal PT, Wijkhuijs JM, Hop W, Verkaik AP, Hilvering C. Expression of the CD11/CD18 cell surface adhesion glycoprotein family on alveolar macrophages in smokers and nonsmokers. Chest. 1991;100:1567-1571.

20. Aguayo SM, King TE, Waldron JA, et al. Increased pulmonary neuroendocrine cells with bombesin-like immunoreactivity in adult patients with eosinophilic granuloma. J Clin Invest. 1990;86:838- 844.

21. Barth J, Kreipe H, Radzun HJ, et al. Increased expression of growth factor genes for macrophages and fibroblasts in bronchoalveolar lavage cells of a patient with pulmonary histiocytosis X. Thorax. 1991;46:835-838.

22. Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol. 1999;163:3511-3515.

23. Gaensler AE, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic and physiological correlations in 502 patients. Ann Thorac Surg. 1980;30:411-426.

24. Agostini C, Albera C, Bariffi F, et al. First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis. 2001;56:364-368.

25. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161:216-223.

26. LaCronique J, Roth C, Battesti JP, Basset F, Chretien J. Chest radiological features of pulmonary histiocytosis, X: a report based on 50 adult cases. Thorax. 1982;37:104-109.

27. Zeppa P, Cozzolino I, Rosso M, et al. Pulmonary Langerhans cell histiocytosis (histiocytosis, X) on bronchoalveolar lavage: a report of 2 cases. Acta Cytol. 2007;51:480-482.

28. Hoover KB, Rosenthal DI, Mankin H. Langerhans cell histiocytosis. Skeletal Radiol. 2007;36:95-104.

29. Birbeck MS, Breathnach AD, Everall JD. An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. J Invest Dermatol. 1961;37:51-64.

30. Huhn D, Konig G,Weig J, SchnellerW. Therapy in pulmonary histiocytosis X. Haematol Bluttransfus. 1981;27:231-237.

31. Von Essen S,WestW, Sitorius M, Rennard SI. Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X. Chest. 1990; 98:765-767.

32. Mendez JL, Nadrous HF, Vassallo K, et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest. 2004;125:1028-1032.

33. Egan AJM, Boardman LA, Tazelaar HD, et al. Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease. Am J Surg Pathol. 1999;23:17-26.

34. Rush WL, Andriko JAW, Galateau-Salle F, et al. Pulmonary pathology of Erdheim-Chester disease. Mod Pathol. 2000;13:747-754.

35. Allen TC, Chevez-Barrios P, Shetlar DJ, Cagle PT. Pulmonary and ophthalmic involvement with Erdheim-Chester disease: a case report and review of the literature. Arch Pathol Lab Med. 2004;128:1428-1431.

36. McClain KL, Natkunam Y, Swedlow SH. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004:283-296.

37. Agarwal A, Pathak S, Gujral S. Sinus histiocytosis with massive lymphadenopathy-a review of seven cases. Indian J Pathol Microbiol. 2006;49:509-515.

38. Huang Q, Change KL, Weiss LM. Extranodal Rosai-Dorfman disease involving the bone marrow: a case report. Am J Surg Pathol. 2006;30:1189-1192.

39. Maric I, Pittaluga S, Dale J, Straus SE, Jaffe ES. Sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Mod Pathol. 2004;17:58A.

40. Bettinardi A, Brugnoni D, Qiros-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89:902-909.

41. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10: 124-133.

42. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341- 1348.

43. Oner AY, Akpek S, Tali T. Rosai-Dorfman disease with epidural and spinal bone marrow involvement: magnetic resonance imaging and diffusion-weighted imaging features. Acta Radiol. 2007;48:331-334.

44. Ben Ghorbel I, Naffati H, Khanfir M, et al. Disseminated form of Rosai-Dorfman disease: a case report. Rev Med Interne. 2005;26:415-419.

45. Ohori NP, Jing Y, Landreneau RJ, Thaete FL. Rosai-Dorfman disease of the pleura: a rare extranodal presentation. Hum Pathol. 2003;1210-1211.

46. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990; 19-73.

47. Travis WD, Colby TV, Koss MN, et al. Non-Neoplastic Disorders of the Lower Respiratory Tract. Washington, DC: Armed Forces Institute of Pathology; 2002:144-147. Atlas of Nontumor Pathology; 1st series, fascicle 2.

48. Buchino JJ, Byrd RP, Kmetz DR. Disseminated sinus histiocytosis with massive lymphadenopathy: its pathologic aspects. Arch Pathol Lab Med. 1982;106: 13-16.

49. Wright DH, Richards DB. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case with widespread nodal and extra nodal dissemination. Histopathology. 1981;5:697-709.

50. Rao NR, Chang C, Uysal N, et al. Fulminate multisystem non- Langerhans cell histiocytic proliferation with hemophagocytosis: a variant form of Erdheim Chester disease. Arch Pathol Lab Med. 2005;129:e39-e43.

51. Kong PM, Pinheiro L, Kaw G, Sittampalam K, Teo CHY. Erdheim- Chester disease: a rare cause of interstitial lung disease. Singapore Med J. 2007;48:e57-e59.

52. Saboerali MD, Koolen MGJ, Noorduyn LA, van Delden OM, Bogaard HJ. Pleural thickening in a construction worker: it is not always mesothelioma. Neth J Med. 2006;64:88-90.

53. Chung JH, Park MS, Shin DH, et al. Pulmonary involvement with Erdheim-Chester disease. Respirology. 2005;10:389-392.

54. Shaburek RD, Brewer HB, Gochuico BR. Erdheim-Chester disease: a rare multisystem histiocytic disorder associated with interstitial lung disease. Am J Med Sci. 2001;321:66-76.

55. Devouassoux G, Laintenjoul S, Chatelain P, et al. Erdheim- Chester disease: a primary macrophage disorder. Am J Respir Crit Care Med. 1998;157:650-653. 56. Wittenberg KH, Swensen SJ, Myers JL, et al. Pulmonary involvement with Erdheim-Chester disease: radiographic and CT findings. Am J Roentgenol. 2000; 174:1271-3331.

57. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease: clinical and radiologic characteristics of 59 cases. Medicine. 1996;75: 157-169.

58. Amir G, Ron N. Pulmonary pathology in Gaucher’s disease. Hum Pathol. 1999;30:666-670.

59. Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine. 2008;75:116-124.

60. Mignot C, Doummar D, Maire I, et al. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28:39- 48.

61. Miller A, Brown LK, Pastores GM, Desnick RJ. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clin Genet. 2003;63:368-376.

62. Rao AR, Parakininkas D, Hintermeyer M, Segura AD, Rice TB. Bilateral lung transplant in Gauchers type-1 disease. Pediatr Transplant. 2005;9:239-243.

63. Dinwiddle R, Sonnappa S. Systemic diseases and the lung. Paediat Resp Rev. 2005;6:181-189.

64. Fisher MR, Sider L. Diffuse reticulonodular infiltration associated with splenomegaly. Chest. 1983;84:609-610.

65. Schneider EL, Epstein CJ, Kaback MJ, et al. Severe pulmonary involvement in Gaucher’s disease: report of three cases and review of the literature. Am J Med. 1977;63:475-480.

66. Wolson AA. Pulmonary findings in Gaucher’s disease. Am J Roentgenol. 1975;123:712-715.

67. Roberts WC, Fredrickson DS. Gaucher’s disease of the lung causing severe pulmonary hypertension with associated acute pericarditis. Circulation. 1967;35: 783-789.

68. Lee RE, Yousem SA. The frequency and type of lung involvement in patients with Gaucher’s disease. Lab Invest. 1988;58:54A.

69. Beutler E. Gaucher disease. Curr Opin Hematol. 1997;4:19-23.

70. Goitein O, Elstein D, Abrahamov A, et al. Lung involvement and enzyme replacement therapy in Gaucher’s disease. Q J Med. 2001;94:407-415.

71. Griffiths GM. Gaucher disease: forging a new path to the lysosome. Cell. 2007;131:67-649.

72. Kelly MM, Leigh R, McKenzie R, et al. Induced sputum examination: diagnosis of pulmonary involvement in Fabry’s disease. Thorax. 2000;55:720-721.

73. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8:539-548.

74. Mohrenschlager M, Pontz BF, Lanzi I, et al. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options. J Dtsch Dermatol Ges. 2007;5:594-597.

75. Kim W, Pyeritz RE, Bernhardt BA, Casey M, Litt HI. Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy. Am J Med Genet Part A. 2007;143A:377-381.

76. Brown LR, Miller A, Bhuptani A, et al. Pulmonary involvement with Fabry disease. Am J Respir Crit Care Med. 1997;155:1004-1010.

77. Peters FP, Sommer A, Vermeulen A, et al. Fabry’s disease: a multidisciplinary disorder. Postgrad Med J. 1997;73:710-712.

78. Rosenberg DM, Ferrans VJ, Fulmer JD, et al. Chronic airflow obstruction in Fabry’s disease. Am J Med. 1980;68:898-905.

79. Nicholson AG, Florio R, Hansell DM, et al. Pulmonary involvement by Niemann-Pick disease: a report of six cases. Histopathology. 2006;596-603.

80. Guillemot N, Troadec C, de Villemeur TB, Clement A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007;42:1207-1214.

81. Mendelson DS, Wasserstein MP, Desnick RJ, et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006;238:339-345.

82. Uyan ZS, Karadag B, Ersu R, et al. Early pulmonary involvement in Niemann-Pick type B disease: lung lavage is not useful. Pediatr Pulmonol. 2005;40: 169-172.

83. Palmeri S, Tarugi P, Sicurelli F, et al. Lung involvement in Niemann-Pick disease type C1: improvement with bronchoalveolar lavage. Neurol Sci. 2005; 26:171-173.

84. Crocker AC, Farber S. Niemann-Pick disease: a review of eighteen patients. Medicine (Baltimore). 1958;37:1-95.

85. Minai OA, Sullivan EJ, Stoller JK. Pulmonary involvement in Niemann-Pick disease: case report and literature review. Resp Med. 2000;94:1241-1251.

86. Skikne MI, Prinsloo I, Webster I. Electron microscopy of lung in Niemann-Pick disease. J Pathol. 1972;106:119-122.

87. Niggemann B, Rebien W, Rahn W, et al. Asymptomatic pulmonary involvement in 2 children with Niemann-Pick disease type B. Respiration. 1994; 61:55-57.

88. Long RG, Lake BD, Petetit JE, et al. Adult Niemann-Pick disease: its relationship to the syndrome of the sea-blue histiocyte. Am J Med. 1977;62:627-635.

89. Nicholson AC, Wells AU, Hooper J, et al. Successful treatment of endogenous lipoid pneumonia due to Niemann-pick Type B disease with whole-lung lavage. Am J Respir Crit Care Med. 2002;165:128- 131.

90. Vellodi A, Hobbs JR, O’Donnell NM, et al. Treatment of Niemann-Pick disease type B by allogenic bone marrow transplantation. Br Med J (Clin Res Ed). 1987;295:1375-1376.

91. Terry RD, Sperry WM, Brodoff B. Adult lipidosis resembling Niemann-Pick’s disease. Am J Pathol. 1954;30:263-285.

92. Verger P, Bentegeat J, Kermarec J, Serville F. Niemann-Pick disease in a 4-year old child without nervous manifestations: considerable significance of pulmonary respiratory signs. Arch Fr Pediatr. 1965;22:1109-1110.

93. Pierson DM, Ionescu D, Qing G, et al. Pulmonary fibrosis in Hermansky-Pudlak syndrome. Respiration. 2006;73:3882-395.

94. Wei ML. Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle dysfunction. Pigment Cell Res. 2006;19:19- 42.

95. Lederer DL, Kaut SM, Sonett JR, et al. Successful bilateral lung transplantation for pulmonary fibrosis associated with Hermansky-Pudlak syndrome. J Heart Lung Transplant. 2005;24:1697- 1699.

96. Brantly M, Villia NA, Shotelersuk V, et al. Pulmonary function and high resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest. 2000;117:129-136.

97. Bachli EB, Brack T, Eppler E, et al. Hermansky-Pudlak syndrome type 4 in a patient from Sri Lanka with pulmonary fibrosis. Am J Met Genet. 2004;127A: 201-207.

98. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002;76: 234-242.

99. Reinila A. Perivascular xanthogranulomatosis in the lungs of diabetic patients. Arch Pathol Lab Med. 1976;100:542-543.

100. Muntoni S, Wiebusch H, Jansen-Rust M, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol. 2007;27:1866-1868.

101. Seedorf U, Wiebusch H, Muntoni S, et al. A novel variant of lysosomal acid lipase (Leu336 ? Pro) associated with acid lipase deficiency and cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol. 1995;15:773-778.

102. Muntoni S, Wiebusch H, Funke H, et al. Homozygosity for a splice junction mutation in exon 8 of the gene encoding lysosomal acid lipase in a Spanish kindred with cholesteryl ester storage disease (CESD). Hum Genet. 1995;95:491-494.

103. Pagani G, Garcia R, Pariyarath R, et al. Expression of lysosomal acid lipase mutants detected in three patients with cholesteryl ester storage disease. Hum Mol Genet. 1996;5:1611-1617.

104. Klima H, Ullrich K, Aslanidis C, et al. A splice junction mutation causes deletion of a 72-base exon from the mRNA for lysosomal acid lipase in a patient with cholesteryl ester storage disease. J Clin Invest. 1993;92:2713-2718.

105. Gasche C, Aslanidis C, Kain R, et al. A novel variant of lysosomal acid lipase in cholesteryl ester storage disease associated with mild phenotype and improvement on lovastatin. J Hepatol. 1997;27:744-750.

106. Redonnnet-Vernhet I, Chatelut M, Basile JP, Salvayre R, Levade T. A novel lysosomal acid lipase gene mutation in a patient with cholesteryl ester storage disease. Hum Mutat. 1998;11:335-336.

107. Ameis D, Brockmann G, Knoblich R, et al. A 5 splice-region mutation and a dinucleotide deletion in the lysosomal acid lipase gene in two patients with cholesteryl ester storage disease. J Lipid Res. 1995;36:241-250.

108. Elleder M, Chlumska A, Hyanek J, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepathol. 2000;32:528-534.

109. Michels VV, Driscoll DJ, Ferry GD, Duff DF, Beaudet AL. Pulmonary vascular obstruction associated with cholesteryl ester storage disease. J Pediatr. 1979; 94:621-623.

110. Cagle PT, Ferry GD, Beaudet AL, et al. Clinicopathologic conference: pulmonary hypertension in an 18-year old girl with cholesteryl ester storage disease (CESD). Am J Med Genet. 1986;24:711-722.

Timothy Craig Allen, MD, JD

Accepted for publication February 14, 2008.

From the Department of Pathology, The University of Texas Health Science Center at Tyler.

The author has no relevant financial interest in the products or companies described in this article.

Reprints: Timothy Craig Allen, MD, JD, Department of Pathology, The University of Texas Health Science Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708 (e-mail: timothy.allen@uthct.edu).

Copyright College of American Pathologists Jul 2008

(c) 2008 Archives of Pathology & Laboratory Medicine. Provided by ProQuest Information and Learning. All rights Reserved.




comments powered by Disqus